Researchers leading a trial of active surveillance for ductal carcinoma in situ (DCIS) have described early results as "reassuring" in a presentation at the 15th European Breast Cancer Conference ...
Ductal carcinoma in situ (DCIS) constitutes a non-invasive precursor to breast cancer in which malignant cells remain confined to the ductal system. Its detection has risen sharply with widespread ...
LAGUNA HILLS, Calif., June 12, 2026 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in precision diagnostics for breast cancer, today highlighted a new milestone for DCISionRT®, its ...
All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE) Tamoxifen 20 mg once-daily reduces the risk of breast cancer recurrence after ductal carcinoma in ...
A trio of large observational studies reported at the San Antonio Breast Cancer Symposium (SABCS) 2025 suggest that GLP-1 receptor agonists may improve outcomes in some women with breast cancer. Two ...
Doctors may be able to spare patients unnecessarily aggressive breast cancer treatments by collecting and testing cancer cells in patients' blood, research from the University of Michigan and the ...
Barcelona, Spain: Researchers leading a trial of active surveillance for ductal carcinoma in situ (DCIS) have described early results as ‘reassuring’ in a presentation to the 15 th European Breast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results